Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Long-term P2Y12-receptor antagonist therapy is crucial for post-myocardial infarction patients.
• Selecting between clopidogrel, prasugrel, and ticagrelor presents a clinical challenge due to varied trial data and bleeding definitions.

Purpose of the Study:

• To compare the efficacy and safety profiles of clopidogrel, prasugrel, and ticagrelor for long-term use in patients post-myocardial infarction.
• To guide clinicians in selecting the optimal P2Y12-receptor antagonist based on patient-specific factors and available evidence.

Main Methods:

• Review and critical appraisal of large clinical trial datasets comparing P2Y12-receptor antagonists.
• Analysis of subgroup data to infer differential ischemic benefits and bleeding risks.
• Consideration of patient characteristics such as renal dysfunction and peripheral arterial disease.

Main Results:

• Prasugrel demonstrates potentially higher anti-ischemic protection compared to clopidogrel, based on available data.
• Ticagrelor emerges as a favorable option for patients with renal dysfunction, peripheral arterial disease, or after short P2Y12-receptor antagonist interruption.
• Clopidogrel may be considered when cost and availability are primary concerns.

Conclusions:

• Direct head-to-head comparative trials between P2Y12-receptor antagonists are lacking.
• Clinical selection should be based on a critical appraisal of existing large clinical datasets and patient-specific factors.
• Individualized treatment selection is paramount for optimizing outcomes in patients requiring long-term P2Y12-receptor antagonist therapy.